UNLABELLED: Prognosis of malignant glioma is very unfavourable mainly due to minimal tumour remnants in the peritumoural tissue. Intralesionally applied radioimmunotherapy is a possible therapeutical option with the potential to improve survival of patients with malignant glioma. We investigated side effects and survival after surgery, conventional radiotherapy and additional radioimmunotherapy with labelled tenascin-antibodies in patients with malignant glioma. METHODS: Since 1995, 37 patients were treated with radioimmunotherapy after resection and radiotherapy of a malignant glioma. Patients received antibodies labelled with yttrium-90 and iodine-131 in different doses into the tumour cavity via a previously implanted ommaya-reservoir. Treatment was applied in up to 8 cycles (mean 2.96 cycles) in time intervals of 6-8 weeks. Mean age was 46 years, histology was anaplastic astrocytoma in 13 patients and glioblastoma in 24 patients. RESULTS: For the whole group median survival time has not yet been reached. For glioblastoma the median survival time is 17 months, 5-year survival probability for anaplastic astrocytoma is 85% approximately. Quality of life was acceptable. Acute side effects following treatment were headache, seizures and worsening of pre-existing neurological symptoms. Late side effects were skin necrosis and, in 1 case, a delayed aphasia probably due to a vascular lesion. CONCLUSION: Radioimmunotherapy prolonged survival time in a selected group of patients with malignant gliomas as compared to a historical control group. Patients with anaplastic astrocytomas seem to have more benefit from this therapy than patients with glioblastomas.
UNLABELLED: Prognosis of malignant glioma is very unfavourable mainly due to minimal tumour remnants in the peritumoural tissue. Intralesionally applied radioimmunotherapy is a possible therapeutical option with the potential to improve survival of patients with malignant glioma. We investigated side effects and survival after surgery, conventional radiotherapy and additional radioimmunotherapy with labelled tenascin-antibodies in patients with malignant glioma. METHODS: Since 1995, 37 patients were treated with radioimmunotherapy after resection and radiotherapy of a malignant glioma. Patients received antibodies labelled with yttrium-90 and iodine-131 in different doses into the tumour cavity via a previously implanted ommaya-reservoir. Treatment was applied in up to 8 cycles (mean 2.96 cycles) in time intervals of 6-8 weeks. Mean age was 46 years, histology was anaplastic astrocytoma in 13 patients and glioblastoma in 24 patients. RESULTS: For the whole group median survival time has not yet been reached. For glioblastoma the median survival time is 17 months, 5-year survival probability for anaplastic astrocytoma is 85% approximately. Quality of life was acceptable. Acute side effects following treatment were headache, seizures and worsening of pre-existing neurological symptoms. Late side effects were skin necrosis and, in 1 case, a delayed aphasia probably due to a vascular lesion. CONCLUSION: Radioimmunotherapy prolonged survival time in a selected group of patients with malignant gliomas as compared to a historical control group. Patients with anaplastic astrocytomas seem to have more benefit from this therapy than patients with glioblastomas.
Authors: T M Behr; R M Sharkey; M E Juweid; R M Dunn; R C Vagg; Z Ying; C H Zhang; L C Swayne; Y Vardi; J A Siegel; D M Goldenberg Journal: J Nucl Med Date: 1997-06 Impact factor: 10.057
Authors: D D Bigner; M T Brown; A H Friedman; R E Coleman; G Akabani; H S Friedman; W L Thorstad; R E McLendon; S H Bigner; X G Zhao; C N Pegram; C J Wikstrand; J E Herndon; N A Vick; N Paleologos; I Cokgor; J M Provenzale; M R Zalutsky Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: K J Murray; D F Nelson; C Scott; A J Fischbach; A Porter; N Farnan; W J Curran Journal: Int J Radiat Oncol Biol Phys Date: 1995-02-01 Impact factor: 7.038
Authors: M T Brown; R E Coleman; A H Friedman; H S Friedman; R E McLendon; R Reiman; G J Felsberg; R D Tien; S H Bigner; M R Zalutsky; X G Zhao; C J Wikstrand; C N Pegram; J E Herndon; N A Vick; N Paleologos; R K Fredericks; S C Schold; D D Bigner Journal: Clin Cancer Res Date: 1996-06 Impact factor: 12.531
Authors: J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér Journal: J Neurooncol Date: 2006-03 Impact factor: 4.130
Authors: J H Mehrkens; G Pöpperl; W Rachinger; J Herms; K Seelos; K Tatsch; J C Tonn; F W Kreth Journal: J Neurooncol Date: 2008-01-23 Impact factor: 4.130
Authors: Hui K Gan; Martin van den Bent; Andrew B Lassman; David A Reardon; Andrew M Scott Journal: Nat Rev Clin Oncol Date: 2017-07-04 Impact factor: 66.675